Patoloxía Molecular das Doenzas Raras
PatMol-DR
GlaxoSmithKline (United Kingdom)
Londres, Reino UnidoPublicacións en colaboración con investigadores/as de GlaxoSmithKline (United Kingdom) (2)
2018
-
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
The Lancet, Vol. 392, Núm. 10157, pp. 1519-1529
2002
-
Oxidative damage and phospholipid fatty acyl composition in skeletal muscle mitochondria from mice underexpressing or overexpressing uncoupling protein 3
Biochemical Journal, Vol. 368, Núm. 2, pp. 597-603